Does Dr. GEORGES ABOU RJAILI have financial conflicts of interest?

Dr. GEORGES ABOU RJAILI (MD) has received a total of $9,241 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $9,184 in personal promotional payouts (consulting, meals, travel) and $56 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. GEORGES ABOU RJAILI?

According to CMS Open Payments data, Dr. GEORGES ABOU RJAILI received funding from MEDTRONIC ($1,999), NOVARTIS PHARMACEUTICALS CORPORATION ($1,330), and E.R. SQUIBB & SONS, L.L.C ($656).

Does Dr. GEORGES ABOU RJAILI receive research grants or speaking fees?

Dr. GEORGES ABOU RJAILI has received $9,184 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $56 in clinical research grants.

DR. GEORGES ABOU RJAILI

MDReal-Time Hydrated

Specialty: Internal Medicine, Cardiovascular Disease

Practice Location: RIVERSIDE, CA 92501

NPI Number: 1073896544

LIFETIME INDUSTRY VALUE

$9,241

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ABOU RJAILI is a verified Internal Medicine, Cardiovascular Disease practitioner based in RIVERSIDE, CA.

Between 2021 and 2024, Dr. ABOU RJAILI had an overall industry promotional and research financial footprint of $9,241 as recorded in the federal CMS Open Payments database.

$9,184 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$56 was allocated to sponsored clinical trials and medical research activities.

Dr. ABOU RJAILI's primary funding source is MEDTRONIC, which accounts for $1,999 (representing 21.6% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

MEDTRONIC

Rank 1

$1,999

21.6%

NOVARTIS PHARMACEUTICALS CORPORATION

Rank 2

$1,330

14.4%

E.R. SQUIBB & SONS, L.L.C

Rank 3

$656

7.1%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.